• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Abdelrahman, R., Abogabal, A., Ismail, A., Marie, S. (2022). THE ROLE OF MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATION OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1. ALEXMED ePosters, 4(3), 35-36. doi: 10.21608/alexpo.2022.163107.1469
Reda Darweesh Mohamed Abdelrahman; Ahmed Abogabal; Amal Shawky Ismail; Salma Elsayed Marie. "THE ROLE OF MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATION OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1". ALEXMED ePosters, 4, 3, 2022, 35-36. doi: 10.21608/alexpo.2022.163107.1469
Abdelrahman, R., Abogabal, A., Ismail, A., Marie, S. (2022). 'THE ROLE OF MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATION OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1', ALEXMED ePosters, 4(3), pp. 35-36. doi: 10.21608/alexpo.2022.163107.1469
Abdelrahman, R., Abogabal, A., Ismail, A., Marie, S. THE ROLE OF MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATION OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1. ALEXMED ePosters, 2022; 4(3): 35-36. doi: 10.21608/alexpo.2022.163107.1469

THE ROLE OF MAGNETIC RESONANCE SPECTROSCOPY IN EVALUATION OF PATIENTS WITH NEUROFIBROMATOSIS TYPE 1

Article 4, Volume 4, Issue 3, September 2022, Page 35-36  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2022.163107.1469
View on SCiNiTO View on SCiNiTO
Authors
Reda Darweesh Mohamed Abdelrahman1; Ahmed Abogabal1; Amal Shawky Ismail2; Salma Elsayed Marie email 1
1Department of Radiodiagnosis and Intervention, Faculty of Medicine, University of Alexandria
2Radiodiagnosis and Intervention, Medicine, Alexandria, Alexandria, Egypt
Abstract
Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder which predisposes patients to develop benign and malignant neoplasms, mostly due to a loss of function mutation in the neurofibromatosis type 1 (NF1) gene. NF1's protein product, neurofibromin, controls Ras pathway inactivation and so functions as a tumor suppressor. A decrease in neurofibromin, which is found in neurons, Schwann cells, and melanocytes, predisposes patients with NF1 to tumors in both the central and peripheral nervous systems. The most common focal brain lesions found in NF1 patients are hamartomas (FASI) and gliomas. Proton Magnetic resonance spectroscopy is one such technique which provides a noninvasive method for characterizing the cellular biochemistry which underlies brain pathologies, helping in differentiating between hamartomas (FASI) and gliomas in our study based on the spectroscopic analysis of different metabolites
AIM OF THE WORK:
This study aimed to assess the role of MR spectroscopy in differentiating between hamartomas (FASI) & gliomas in NF1 patients. And assessing the metabolite differences in the normal appearing brain of NF1 patients and normal healthy volunteers.
Keywords
Neurofibromatosis type 1 (NF1); MAGNETIC RESONANCE SPECTROSCOPY; hamartomas (FASI) and gliomas
Supplementary Files
download 1469 - 10.pdf
Statistics
Article View: 146
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.